Japan· JP-1319744Q1046
レボブノロール塩酸塩
A levobunolol product containing レボブノロール塩酸塩, registered in Japan by ロートニッテン, on the national reimbursement list. The same ATC class is registered in 8 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Levobunolol is registered in 8 of 19 countries.
Countries holding a registration under ATC S01ED03 (levobunolol), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 4 of them publish a price we can compare per daily dose
Levobunolol · ATC S01ED03
8 / 19 countries
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レボブノロール塩酸塩
- Manufacturer
- ロートニッテン
- Country
- Japan (JP)
- ATC code
- S01ED03
- ATC class
- Levobunolol
- Defined daily dose
- 0.2 ml, AT
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
127 interactions on record for levobunolol.
Graded by severity as the source publishes them — 26 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levobunolol · interactions on record
127 records
- 26 severe
- 68 moderate
- 2 minor
- 31 info
Most severe, free to view
- EpinephrineB02BC09severe
- EpinephrineC01CA24severe
- OrciprenalinC01CA29severe
- TheophyllinC01EB28severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under S01ED03
Levobunolol, as other registers publish it.
- FinlandBetaganAllergan Limited
- FranceBETAGAN 0,5 % , collyre en solution en récipient unidoseABBVIE
- United KingdomBetagan 0.5% eye dropsLexon (UK) Ltd
- United KingdomBetagan 0.5% eye dropsNecessity Supplies Ltd
- United KingdomBetagan 0.5% eye dropsDE Pharmaceuticals
- United KingdomBetagan 0.5% eye dropsDowelhurst Ltd
- United KingdomBetagan 0.5% eye dropsSigma Pharmaceuticals Plc
- United KingdomBetagan 0.5% eye dropsWaymade Healthcare Plc
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1969ad8-962b-408f-87a4-9328e1e56a6e GET /v1/drugs/b1969ad8-962b-408f-87a4-9328e1e56a6e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．５％１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1319744Q1046",
"category": "外用薬",
"price_yen": 138.8,
"generic_name": "レボブノロール塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1319",
"transitional_expiry": null
}See everything about levobunolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.